Loading...
•
Sep 30, 2024
CervoMed Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
CervoMed reported a net loss of $4.8 million for the third quarter of 2024, compared to a net income of $2.2 million for the same period in 2023. As of September 30, 2024, CervoMed had approximately $46.7 million in cash, cash equivalents and marketable securities.
Completed final patient visits in RewindD-LB Phase 2b trial evaluating neflamapimod in patients with early-stage DLB and began preparing for database lock.
Topline data from the RewindD-LB study is expected in December 2024.
Preparing for Phase 3 trial initiation in mid-2025 after planned end-of-Phase 2 meeting with the FDA.
Plan to initiate a Phase 2a trial to evaluate neflamapimod’s potential to promote recovery from ischemic stroke in the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...